Tura S, Cavo M, Rosti G, Bandini G, Gobbi M, Grimaldi M, Miggiano M C, Albertazzi L, Bonelli M A
Institute of Haematology, L. e A. Seràgnoli, University of Bologna, Italy.
Bone Marrow Transplant. 1989 Dec;4 Suppl 4:106-8.
Seventeen patients received marrow transplants from their HLA-matched, MLC-negative, sibling donors. Nine patients had progressive disease not responding to conventional treatments, while the other 8 patients were rated as responders. The most frequently used conditioning regimen consisted of total body irradiation and high-dose multi-agent chemotherapy with cyclophosphamide plus either oral melphalan (5 cases) or BCNU (1 case) on both these drugs (7 cases). Twelve patients were valuable for response to BTM: 7 of them (6 responders and 1 with advanced refractory MM) entered complete remission, while 5 had sustained decrease in tumor mass that ranged between 72% and 93%. Eleven patients died of transplant-related causes, 1 of them with signs of progressive disease. The remaining 6 patients are alive and 5 of them maintain a complete remission status 4 to 67 (median 36) months after BMT.
17名患者接受了来自与其HLA匹配、混合淋巴细胞培养阴性的同胞供者的骨髓移植。9名患者患有对传统治疗无反应的进展性疾病，而其他8名患者被评为有反应者。最常用的预处理方案包括全身照射和大剂量多药化疗，其中环磷酰胺加口服美法仑（5例）或卡氮芥（1例），两种药物联合使用（7例）。12名患者对骨髓移植的反应具有评估价值：其中7名（6名有反应者和1名晚期难治性多发性骨髓瘤患者）进入完全缓解期，而5名患者的肿瘤肿块持续缩小，缩小范围在72%至93%之间。11名患者死于移植相关原因，其中1名有疾病进展的迹象。其余6名患者存活，其中5名在骨髓移植后4至67个月（中位时间36个月）保持完全缓解状态。
